Monoclonal Antibody Therapeutics Market

Monoclonal Antibody (mAb) Therapeutics Market, By Source (Human, Humanized, Chimeric, Murine); By Application/Therapy Area (Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, Cardiovascular Diseases, Others); By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa), Global Trend Analysis, Competitive Landscape & Forecast, 2019–2031
- Published Date: February 2025
- Report ID: BWC25080
- Available Format: PDF
- Page: 512
Report Overview
Increasing prevalence of chronic diseases, rising R&D investments, and expanding applications of mAbs are expected to boost the growth of Global Monoclonal Antibody (mAb) Therapeutics Market during the forecast period between 2025 and 2031.
Global Monoclonal Antibody (mAb) Therapeutics Market - Industry Trends & Forecast Report, 2031
Global Monoclonal Antibody (mAb) Therapeutics Market size was estimated to be worth USD 273.2 billion in 2024. During the forecast period between 2025 and 2031, Global Monoclonal Antibody (mAb) Therapeutics Market size is projected to grow at a robust CAGR of 11.2% reaching a value of USD 559.3 billion by 2031. Major growth factors for Global Monoclonal Antibody (mAb) Therapeutics Market include the rising prevalence of chronic diseases such as cancer and cardiovascular conditions, which are increasing the demand for biologics, as well as the growing use of mAb therapies in targeted treatments. Additionally, heightened awareness among patients and physicians about the effectiveness of mAb therapies is expected to further boost market expansion. Monoclonal antibodies, produced through cell lines or clones derived from immunized animals, play a crucial role in medical advancements, with their ability to target specific disease markers and pathogens contributing to their widespread use. The development of mAbs for COVID-19 treatment, including the FDA’s emergency use authorization of Eli Lilly’s bebtelovimab, has further accelerated market growth. The advantages of mAb therapies—such as specificity, effectiveness, and ease of delivery—have led to numerous product launches and approvals, with more than 100 mAb products receiving FDA approval. Innovations in antibody fragments, bispecific antibodies, and other advanced treatments are expected to expand therapeutic applications, while strategic initiatives by key market players continue to drive further growth.
Monoclonal Antibody (mAb) Therapeutics – Overview
Monoclonal Antibody (mAb) Therapeutics refers to a class of biologic drugs made from identical immune cells that are clones of a single parent cell. These antibodies are designed to target specific antigens, such as disease markers or pathogens, and can be used for a wide range of therapeutic applications, including the treatment of cancers, autoimmune diseases, infectious diseases, and cardiovascular conditions. mAbs are produced through cell lines derived from immunized animals and have gained significant attention due to their high specificity, effectiveness, and ability to provide targeted treatment with minimal side effects.
Global Monoclonal Antibody (mAb) Therapeutics Market
Growth Drivers
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases, including cancer, rheumatoid arthritis, and hepatitis B, is significantly driving Global Monoclonal Antibody (mAb) Therapeutics Market. These targeted therapies enhance immune responses by recognizing specific proteins on cells, offering effective treatment solutions. Over the past three decades, more than 100 monoclonal antibody therapies have been approved, revolutionizing disease management and improving patient outcomes. Additionally, the rise in infectious diseases such as COVID-19, Ebola, and HIV has expanded the scope of mAbs, demonstrating their critical role in modern medicine. Innovations like VIR-3434, which shows promise in treating chronic hepatitis B and D, further highlight the growing applications of mAbs. However, market accessibility remains a challenge, with high-income countries dominating adoption while affordability limits access in low- and middle-income regions. Addressing regulatory hurdles, investing in R&D, and enhancing production efficiency will be vital in ensuring equitable global access, driving sustained market growth and improving healthcare outcomes worldwide.
Challenges
High Cost of mAb Therapies
The high cost of monoclonal antibody (mAb) therapies is a significant barrier to market expansion, limiting accessibility and affordability for patients worldwide. Producing mAbs involves complex biotechnological processes, including cell culture, purification, and stringent quality control measures, which drive up manufacturing costs. On average, mAb therapies cost between USD 15,000 and USD 200,000 per patient per year, making them unaffordable for many, especially in low- and middle-income countries. Additionally, these high costs place a financial burden on healthcare systems and insurance providers, restricting widespread adoption. Despite the growing demand for targeted biologic treatments in oncology, autoimmune disorders, and infectious diseases, the prohibitive pricing curtails patient access and slows market penetration. Efforts to reduce costs, such as biosimilar development and innovative manufacturing techniques, aim to address this challenge. However, until pricing barriers are significantly lowered, Global mAbs Therapeutics Market will continue to face growth constraints.
Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market
Escalating geopolitical tensions could present both opportunities and challenges for Global Monoclonal Antibody (mAb) Therapeutics Market. Trade restrictions, supply chain disruptions, and regulatory uncertainties may hinder the production and distribution of mAbs, increasing costs and limiting patient access. Additionally, geopolitical instability could affect pharmaceutical collaborations and investment in biologic drug development. However, heightened government focus on healthcare security and domestic biopharmaceutical manufacturing could drive regional production capabilities and reduce dependence on imports. While geopolitical uncertainties create barriers, they also encourage innovation in supply chain resilience and alternative manufacturing strategies, shaping the future growth of the mAb therapeutics market.
Global Monoclonal Antibody (mAb) Therapeutics Market
Segmental Coverage
Global Monoclonal Antibody (mAb) Therapeutics Market – By Source
Based on source, Global Monoclonal Antibody (mAb) Therapeutics Market is divided into Human, Humanized, Chimeric, and Murine segments. The human segment holds the highest share in Global Monoclonal Antibody (mAb) Therapeutics Market by source. Human-derived mAbs are widely used in tumor immunotherapy, medical imaging, and neutralizing toxins, viruses, and drug overdoses due to their superior efficacy and safety. Unlike mouse-derived mAbs, which may trigger immune responses, human-origin mAbs exhibit lower immunogenicity and efficiently modulate effector functions. Advanced techniques like phage display and hybridoma technology in transgenic mice enable their production. With continuous advancements in genetic engineering, the development and adoption of fully human mAbs are expected to rise, further enhancing therapeutic interventions and patient outcomes.
Global Monoclonal Antibody (mAb) Therapeutics Market – By Application/Therapeutic Area
Global Monoclonal Antibody (mAb) Therapeutics Market by application/therapeutic area is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, Cardiovascular Diseases, and other therapeutic areas. The oncology segment holds the highest share in Global Monoclonal Antibody (mAb) Therapeutics Market by application/therapeutic area, driven by the increasing number of regulatory approvals for mAbs targeting various types of cancer. The rising incidence of cancer is a key factor fueling this growth, as mAbs offer fewer side effects compared to other drugs and chemotherapy. Current mAb treatments target cancers such as non-small cell lung cancer, brain tumors, ovarian, breast, gastric, melanoma, colorectal cancer, and Hodgkin’s lymphoma. Additionally, the use of mAbs for autoimmune diseases, particularly rheumatoid arthritis, is expected to grow rapidly due to the rising prevalence of these conditions and the identification of cytokine proteins involved in inflammatory pathways that can be targeted for disease mitigation. mAbs are designed to bind to specific proteins on cancer cells, either killing them or inhibiting their growth. With a broad range of mAb therapies available, some target specific cancers and others effective across multiple types, their effectiveness and versatility in oncology are driving advancements and growth in cancer treatment strategies.Bottom of Form
Global Monoclonal Antibody (mAb) Therapeutics Market – By Distribution Channel
On the basis of distribution channel, Global Monoclonal Antibody (mAb) Therapeutics Market is segmented into Hospitals, Retail Pharmacies, and Online Pharmacies segments.
Global Monoclonal Antibody (mAb) Therapeutics Market – By Region
The in-depth research report on Global Monoclonal Antibody (mAb) Therapeutics Market covers a number of country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA). North America region dominates Global Monoclonal Antibody (mAb) Therapeutics Market, driven by substantial healthcare expenditures, particularly in United States, where spending significantly surpasses that of other countries, although it does not always lead to better healthcare outcomes. High service prices and utilization rates contribute to the rising costs in United States. Meanwhile, Canada’s medical sector is thriving, supported by innovative research, technological advancements, and growing demand for healthcare services. This dynamic evolution in Canada’s healthcare system further strengthens the region's position and growth potential in the monoclonal antibody therapeutics market. In January 2022, GSK and Vir Biotechnology secured an agreement with the United States government to purchase additional supplies of sotrovimab, which has been authorized for early COVID-19 treatment.
Competitive Landscape
Global Monoclonal Antibody (mAb) Therapeutics Market is highly competitive, as a number of companies are competing to gain a significant market share. Key players in the market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
Recent Developments
-
In February 2024 - AbbVie and OSE Immunotherapeutics formed a collaboration to advance the development of a new monoclonal antibody (mAb) aimed at addressing chronic inflammation.
Scope of the Report
Attributes |
Details |
Years Considered |
Historical Data – 2019–2024 |
Base Year – 2024 |
|
Estimated Year – 2025 |
|
Forecast Period – 2025–2031 |
|
Facts Covered |
Revenue in USD Billion |
Market Coverage |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Product/ Service Segmentation |
Source, Application, Distribution Channel, Region |
Key Players |
F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, Thermo Fisher Scientific Inc |
By Source
-
Human
-
Humanized
-
Chimeric
-
Murine
By Application/Therapy Area
-
Oncology
-
Autoimmune Diseases
-
Infectious Diseases
-
Hematological Disorders
-
Cardiovascular Diseases
-
Others
By Distribution Channel
-
Hospitals
-
Retail Pharmacies
-
Online Pharmacies
By Region
-
North America
-
Europe
-
Asia Pacific (APAC)
-
Latin America (LATAM)
-
Middle East and Africa (MEA)
- Research Framework
- Research Objective
- Product Overview
- Market Segmentation
- Executive Summary
- Global Monoclonal Antibody (mAb) Therapeutics Market Insights
- End User Value Chain Analysis
- DROC Analysis
- Growth Drivers
- Increasing Prevalence of Chronic Diseases
- Growing Investments in (mAb) R&D Programs
- Expanding Applications
- Restraints
- High Cost of (mAb) Therapies
- Stringent Regulatory Requirements
- Opportunities
- Developing Novel (mAb) Therapies
- Growing Adoption of Personalized Medicines
- Challenges
- Competitions from Biosimilars
- Potential Side Effects
- Growth Drivers
- Technological Advancements/Recent Developments
- Regulatory Framework
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Global Monoclonal Antibody (mAb) Therapeutics Market: Marketing Strategies
- Global Monoclonal Antibody (mAb) Therapeutics Market: Pricing Analysis
- Global Monoclonal Antibody (mAb) Therapeutics Market: Geography Analysis
- Global Monoclonal Antibody (mAb) Therapeutics Market, Geographical Analysis, 2024
- Global Monoclonal Antibody (mAb) Therapeutics, Market Attractiveness Analysis, 2024–2031
- Global Monoclonal Antibody (mAb) Therapeutics Market Overview
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- Human
- Humanized
- Chimeric
- Murine
- By Application/Therapy Area
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Hematological Disorders
- Cardiovascular Diseases
- Others
- By Distribution Channel
- Hospitals
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific (APAC)
- Latin America (LATAM)
- Middle East and Africa (MEA)
- By Source
- Market Size & Forecast, 2019–2031
- North America Monoclonal Antibody (mAb) Therapeutics Market
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- By Application
- By Distribution Channel
- By Country
- United States
- By Source
- By Application
- By Distribution Channel
- Canada
- By Source
- By Application
- By Distribution Channel
- United States
- Market Size & Forecast, 2019–2031
- Europe Monoclonal Antibody (mAb) Therapeutics Market
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- By Application
- By Distribution Channel
- By Country
- Germany
- By Source
- By Application
- By Distribution Channel
- United Kingdom
- By Source
- By Application
- By Distribution Channel
- Italy
- By Source
- By Application
- By Distribution Channel
- France
- By Source
- By Application
- By Distribution Channel
- Spain
- By Source
- By Application
- By Distribution Channel
- Belgium
- By Source
- By Application
- By Distribution Channel
- Russia
- By Source
- By Application
- By Distribution Channel
- The Netherlands
- By Source
- By Application
- By Distribution Channel
- Rest of Europe
- By Source
- By Application
- By Distribution Channel
- Germany
- Market Size & Forecast, 2019–2031
- Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- By Application
- By Distribution Channel
- By Country
- China
- By Source
- By Application
- By Distribution Channel
- India
- By Source
- By Application
- By Distribution Channel
- Japan
- By Source
- By Application
- By Distribution Channel
- South Korea
- By Source
- By Application
- By Distribution Channel
- Australia and New Zealand
- By Source
- By Application
- By Distribution Channel
- Indonesia
- By Source
- By Application
- By Distribution Channel
- Malaysia
- By Source
- By Application
- By Distribution Channel
- Singapore
- By Source
- By Application
- By Distribution Channel
- Vietnam
- By Source
- By Application
- By Distribution Channel
- Rest of APAC
- By Source
- By Application
- By Distribution Channel
- China
- Market Size & Forecast, 2019–2031
- Latin America Monoclonal Antibody (mAb) Therapeutics Market
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- By Application
- By Distribution Channel
- By Country
- Brazil
- By Source
- By Application
- By Distribution Channel
- Mexico
- By Source
- By Application
- By Distribution Channel
- Argentina
- By Source
- By Application
- By Distribution Channel
- Peru
- By Source
- By Application
- By Distribution Channel
- Rest of LATAM
- By Source
- By Application
- By Distribution Channel
- Brazil
- Market Size & Forecast, 2019–2031
- Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market
- Market Size & Forecast, 2019–2031
- By Value (USD Billion)
- Market Share & Forecast
- By Source
- By Application
- By Distribution Channel
- By Country
- Saudi Arabia
- By Source
- By Application
- By Distribution Channel
- UAE
- By Source
- By Application
- By Distribution Channel
- Qatar
- By Source
- By Application
- By Distribution Channel
- Kuwait
- By Source
- By Application
- By Distribution Channel
- South Africa
- By Source
- By Application
- By Distribution Channel
- Nigeria
- By Source
- By Application
- By Distribution Channel
- Algeria
- By Source
- By Application
- By Distribution Channel
- Rest of MEA
- By Source
- By Application
- By Distribution Channel
- Saudi Arabia
- Market Size & Forecast, 2019–2031
- Competitive Landscape
- List of Key Players and Their Offerings
- Global Monoclonal Antibody (mAb) Therapeutics Company Market Share Analysis, 2024
- Competitive Benchmarking, By Operating Parameters
- Key Strategic Developments (Mergers, Acquisitions, Partnerships)
- Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market
- Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Johnson & Johnson Services, Inc.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Amgen Inc
- Bristol Myers Squibb Company (US)
- Merck & Co Inc
- AstraZeneca plc
- Sanofi
- Bayer AG
- Eli Lilly and Company
- Thermo Fisher Scientific Inc
- Other Prominent Players
- Key Strategic Recommendations
- Research Methodology
- Qualitative Research
- Primary & Secondary Research
- Quantitative Research
- Market Breakdown & Data Triangulation
- Secondary Research
- Primary Research
- Breakdown of Primary Research Respondents, By Region
- Assumptions & Limitations
- Qualitative Research
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
Figure 1 Global Monoclonal Antibody (mAb) Therapeutics Segmentation
Figure 2 Global Monoclonal Antibody (mAb) Therapeutics Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2024
Figure 4 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 5 Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 6 Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 7 Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 8 Global Monoclonal Antibody (mAb) Therapeutics Market Share, By Region, By Value (USD Billion), 2019–2031
Figure 9 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 10 North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 11 North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 12 North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 13 North America Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031
Figure 14 United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 15 United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 16 United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 17 United States Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 18 Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 19 Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 20 Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 21 Canada Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 22 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 23 Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 24 Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 25 Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 26 Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031
Figure 27 Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 28 Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 29 Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 30 Germany Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 31 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 32 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 33 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 34 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 35 Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 36 Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 37 Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 38 Italy Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 39 France Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 40 France Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 41 France Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 42 France Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 43 Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 44 Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 45 Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 46 Spain Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 47 Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 48 Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 49 Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 50 Belgium Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 51 Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 52 Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 53 Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 54 Russia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 55 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 56 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 57 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 58 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 59 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 60 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 61 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 62 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 63 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 64 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 65 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 66 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 67 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031
Figure 68 China Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 69 China Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 70 China Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 71 China Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 72 India Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 73 India Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 74 India Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 75 India Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 76 Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 77 Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 78 Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 79 Japan Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 80 South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 81 South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 82 South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 83 South Korea Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 84 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 85 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 86 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 87 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 88 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 89 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 90 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 91 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 92 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 93 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 94 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 95 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 96 Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 97 Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 98 Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 99 Singapore Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 100 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 101 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 102 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 103 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 104 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 105 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 106 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 107 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 108 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 109 Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 110 Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 111 Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 112 Latin America Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031
Figure 113 Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 114 Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 115 Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 116 Brazil Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 117 Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 118 Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 119 Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 120 Mexico Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 121 Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 122 Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 123 Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 124 Argentina Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 125 Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 126 Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 127 Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 128 Peru Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 129 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 130 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 131 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 132 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 133 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 134 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 135 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 136 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 137 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Country, By Value (USD Billion), 2019–2031
Figure 138 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 139 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 140 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 141 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 142 UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 143 UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 144 UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 145 UAE Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 146 Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 147 Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 148 Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 149 Qatar Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 150 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 151 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 152 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 153 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 154 South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 155 South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 156 South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 157 South Africa Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 158 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 159 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 160 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 161 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 162 Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 163 Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 164 Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 165 Algeria Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
Figure 166 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Figure 167 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Source, By Value (USD Billion), 2019–2031
Figure 168 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Application, By Value (USD Billion), 2019–2031
Figure 169 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Share, By Distribution Channel, By Value (USD Billion), 2019–2031
List of Tables
Table 1 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 2 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 3 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 4 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 5 Global Monoclonal Antibody (mAb) Therapeutics Market Size, By Region, By Value (USD Billion), 2019–2031
Table 6 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 7 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 8 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 9 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 10 North America Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031
Table 11 United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 12 United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 13 United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 14 United States Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 15 Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 16 Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 17 Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 18 Canada Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 19 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 20 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 21 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 22 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 23 Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031
Table 24 Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 25 Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 26 Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 27 Germany Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 28 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 29 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 30 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 31 United Kingdom Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 32 Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 33 Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 34 Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 35 Italy Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 36 France Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 37 France Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 38 France Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 39 France Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 40 Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 41 Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 42 Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 43 Spain Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 44 Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 45 Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 46 Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 47 Belgium Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 48 Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 49 Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 50 Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 51 Russia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 52 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 53 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 54 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 55 The Netherlands Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 56 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 57 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 58 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 59 Rest of Europe Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 60 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 61 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 62 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 63 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 64 Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031
Table 65 China Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 66 China Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 67 China Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 68 China Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 69 India Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 70 India Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 71 India Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 72 India Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 73 Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 74 Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 75 Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 76 Japan Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 77 South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 78 South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 79 South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 80 South Korea Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 81 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 82 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 83 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 84 Australia and New Zealand Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 85 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 86 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 87 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 88 Indonesia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 89 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 90 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 91 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 92 Malaysia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 93 Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 94 Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 95 Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 96 Singapore Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 97 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 98 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 99 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 100 Vietnam Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 101 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 102 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 103 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 104 Rest of APAC Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 105 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 106 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 107 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 108 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 109 Latin America Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031
Table 110 Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 111 Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 112 Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 113 Brazil Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 114 Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 115 Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 116 Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 117 Mexico Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 118 Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 119 Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 120 Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 121 Argentina Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 122 Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 123 Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 124 Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 125 Peru Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 126 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 127 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 128 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 129 Rest of LATAM Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 130 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 131 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 132 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 133 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 134 Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Country, By Value (USD Billion), 2019–2031
Table 135 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 136 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 137 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 138 Saudi Arabia Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 139 UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 140 UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 141 UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 142 UAE Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 143 Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 144 Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 145 Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 146 Qatar Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 147 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 148 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 149 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 150 Kuwait Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 151 South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 152 South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 153 South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 154 South Africa Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 155 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 156 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 157 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 158 Nigeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 159 Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 160 Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 161 Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 162 Algeria Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 163 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Value (USD Billion), 2019–2031
Table 164 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Source, By Value (USD Billion), 2019–2031
Table 165 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Application, By Value (USD Billion), 2019–2031
Table 166 Rest of MEA Monoclonal Antibody (mAb) Therapeutics Market Size, By Distribution Channel, By Value (USD Billion), 2019–2031
Table 167 F. Hoffmann-La Roche Ltd Company Overview
Table 168 F. Hoffmann-La Roche Ltd Financial Overview
Table 169 Novartis AG Company Overview
Table 170 Novartis AG Financial Overview
Table 171 Johnson & Johnson Services, Inc. Company Overview
Table 172 Johnson & Johnson Services, Inc. Financial Overview
Table 173 GlaxoSmithKline plc Company Overview
Table 174 GlaxoSmithKline plc Financial Overview
Table 175 Merck & Co., Inc. Company Overview
Table 176 Merck & Co., Inc. Financial Overview
Table 177 Amgen Inc Company Overview
Table 178 Amgen Inc Financial Overview
Table 179 Bristol Myers Squibb Company (US) Company Overview
Table 180 Bristol Myers Squibb Company (US) Financial Overview
Table 181 Merck & Co Inc Company Overview
Table 182 Merck & Co Inc Financial Overview
Table 183 AstraZeneca plc Company Overview
Table 184 AstraZeneca plc Financial Overview
Table 185 Sanofi Company Overview
Table 186 Sanofi Financial Overview
Table 187 Bayer AG Company Overview
Table 188 Bayer AG Financial Overview
Table 189 Eli Lilly and Company: Company Overview
Table 190 Eli Lilly and Company Financial Overview
Table 191 Thermo Fisher Scientific Inc Company Overview
Table 192 Thermo Fisher Scientific Inc Financial Overview
Market Segmentation
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
Frequently Asked Questions (FAQs):
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.